TENX
Tenax Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Nov. 18, 9:18 AM
    • Tenax Therapeutics (NASDAQ:TENX) completes the enrollment of 880 subjects in its Phase 3 clinical trial, LEVO-CTS, assessing the use of levosimendan administered before and during cardiac surgery to reduce the incidence of low cardiac output syndrome and associated morbidity and mortality, an FDA Fast Track designation.
    • Levosimendan is a calcium sensitizer that was originally developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Tenax acquired the North American rights from Phyxius Pharma.
    | Fri, Nov. 18, 9:18 AM | 15 Comments
  • Thu, Nov. 10, 10:19 AM
    • Tenax Therapeutics (TENX -1.3%) Q3 results: Revenues: $0; R&D Expense: $3.2M (+88.2%); SG&A: $1.3M (-7.1%); Operating Loss: ($4.5M) (-45.2%); Net Loss: ($4.3M) (-48.3%); Loss Per Share: ($0.15) (-50.0%); Quick Assets: $7.5M (-62.9%).
    • Financial Guidance:Tenax continues to expect that its cash balance, including the fair value of its marketable securities, will be sufficient for it to accomplish its corporate goals through 2017, including the full readout of its ongoing Phase 3 LEVO-CTS trial and a potential New Drug Application for levosimendan in the LCOS indication in 2017. Tenax continues to anticipate that its cash balance at the end of 2016 will be between $19 and $20 million.
    | Thu, Nov. 10, 10:19 AM
  • Thu, Nov. 10, 6:01 AM
    | Thu, Nov. 10, 6:01 AM
  • Wed, Oct. 5, 11:01 AM
    | Wed, Oct. 5, 11:01 AM
  • Thu, Aug. 11, 8:49 AM
    • Tenax Therapeutics (TENX) Q2 results: Revenues: $0; R&D Expense: $3.4M (+78.9%); SG&A: $1.2M (-93.7%); Operating Loss: ($4.7M) (+4.1%); Net Loss: ($4.6M) (+2.1%); Loss Per Share: ($0.17) (unch); Quick Assets: $10M (-50.5%).
    • Financial Guidance: The company continues to expect that its cash balance, including the fair value of its marketable securities, will be sufficient for it to accomplish its corporate goals through 2017, including the full readout of its ongoing Phase 3 LEVO-CTS trial and a potential New Drug Application for levosimendan in the LCOS indication. Tenax currently anticipates that its cash balance at the end of 2016 will be between $19 and $20 million.
    | Thu, Aug. 11, 8:49 AM
  • Thu, Aug. 11, 6:02 AM
    | Thu, Aug. 11, 6:02 AM
  • Thu, May 19, 6:28 AM
    • Tenax Therapeutics (TENX) Q1 results: Revenues: $0; R&D Expense: $3.9M (+143.8%); SG&A: $1.8M (+12.5%); Operating Loss: ($5.7M) (-78.1%); Net Loss: ($5.4M) (-86.2%); Loss Per Share: ($0.19) (-90.0%); Quick Assets: $15.8M (-21.8%); CF Ops: ($3.3M) (-32.0%).
    • Financial Guidance: The Company continues to expect that its cash balance, including the fair value of its marketable securities, will be sufficient for it to accomplish its corporate goals through 2017, including the full readout of its ongoing Phase 3 LEVO-CTS trial and a potential New Drug Application for levosimendan in the LCOS indication.
    | Thu, May 19, 6:28 AM
  • Thu, May 19, 1:48 AM
    • Tenax Therapeutics (NASDAQ:TENX): Q1 EPS of -$0.19 misses by $0.05.
    • Cash and cash equivalents of $3.3M.
    | Thu, May 19, 1:48 AM
  • Wed, Mar. 16, 8:19 AM
    • Tenax Therapeutics (NASDAQ:TENX): 8M'15 EPS of -$0.36
    | Wed, Mar. 16, 8:19 AM
  • Dec. 15, 2015, 7:25 AM
    • Tenax Therapeutics (TENX +1%) FQ2 results: Revenues: $0; R&D Expense: $2.5M (-3.8%); SG&A: $1.2M (-25.0%); Operating Loss: ($3.7M) (+9.8%); Net Loss: ($3.5M) (+14.6%); Loss Per Share: ($0.13) (+7.1%); Quick Assets: $21.7M (+26.9%).
    • No guidance given.
    | Dec. 15, 2015, 7:25 AM
  • Dec. 15, 2015, 3:56 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ2 EPS of -$0.13 beats by $0.01.
    • 10Q
    | Dec. 15, 2015, 3:56 AM
  • Sep. 14, 2015, 6:16 AM
    • Tenax Therapeutics (TENX -0.8%) FQ1 results: Revenues: $0; R&D Expense: $1.7M (+70.0%); SG&A: $1.37M (-5.5%); Operating Loss: ($3.1M) (-29.2%); Net Loss: ($3M) (-36.4%); Loss Per Share: ($0.11) (-37.5%); Quick Assets: $21.3M (+24.6%).
    • No guidance given.
    | Sep. 14, 2015, 6:16 AM
  • Sep. 14, 2015, 6:04 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ1 EPS of -$0.11 beats by $0.03.
    | Sep. 14, 2015, 6:04 AM
  • Jul. 16, 2015, 6:22 AM
    • Tenax Therapeutics (TENX -1.3%) FY15 results: Revenues: $0; R&D Expense: $6.7M (+123.3%); SG&A: $7.2M (-47.8%); Operating Loss: ($14.8M) (+10.8%); Net Loss: ($14.1M) (+44.3%); Loss Per Share: ($0.50) (+81.5%); Quick Assets: $17.1M (-70.7%).
    • No guidance given.
    | Jul. 16, 2015, 6:22 AM
  • Jul. 16, 2015, 6:05 AM
    • Tenax Therapeutics (NASDAQ:TENX): FY15 EPS of -$0.50
    | Jul. 16, 2015, 6:05 AM
  • Mar. 18, 2015, 6:28 AM
    • Tenax Therapeutics (TENX) FQ3 results: Revenues: $0; R&D Expense: $1.2M (+71.4%); SG&A: $1.9M (+5.6%); Operating Loss: ($3.1M) (-29.2%); Net Loss: ($2.9M) (+14.7%); Loss Per Share: ($0.10) (+77.3%); Quick Assets: $17.1M (-70.7%).
    • No guidance given.
    | Mar. 18, 2015, 6:28 AM